30 Geographic Atrophy Clinical Trials in Phoenix, AZ (2026)

Q: How do I join a clinical trial in Phoenix?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Phoenix research site will contact you.

Recruiting Geographic Atrophy Studies in Phoenix

NCT00358943Recruiting

International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatme...

Phoenix, AZ12,000 participantsGenzyme, a Sanofi Company

View Study Details

NCT07431281Recruiting

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positiv...

Phoenix, AZPHASE32,130 participantsAstraZeneca

View Study Details

NCT05633654Recruiting

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatmen...

Phoenix, AZPHASE31,514 participantsGilead Sciences

View Study Details

NCT02523118Recruiting

OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages

The purpose of this observational study is to find the best measures to define how well a person with eosinophilic disorder is doing. People with EoE, EoG, EoN and EoC normally undergo endoscopy and/o...

Phoenix, AZ1,350 participantsChildren's Hospital Medical Center, Cincinnati

View Study Details

NCT02423070Recruiting

Genome Transplant Dynamics

Study Description: Heart and lung transplants can save lives, but long-term success is often limited by organ rejection that is hard to detect early. This study is testing a new, non-invasive blood t...

Phoenix, AZ991 participantsNational Heart, Lung, and Blood Institute (NHLBI)

View Study Details

NCT07700979Recruiting

Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma

The goal of this randomized, double-blind, multi-regional phase 3 study of cadonilimab combined with chemotherapy versus chemotherapy in combination with or without nivolumab for the first-line treatm...

Phoenix, AZPHASE3900 participantsAkeso

View Study Details

NCT06764875Recruiting

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

This is a Phase Ⅲ, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) c...

Phoenix, AZPHASE3840 participantsAstraZeneca

View Study Details

NCT03126916Recruiting

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

This phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, s...

Phoenix, AZPHASE3750 participantsChildren's Oncology Group

View Study Details

NCT07221149Recruiting

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

The purpose of this study is to evaluate the safety and efficacy of Pumitamig in combination with chemotherapy versus Nivolumab in combination with chemotherapy in participants with previously untreat...

Phoenix, AZPHASE2690 participantsBristol-Myers Squibb

View Study Details

NCT05046600Recruiting

Registry of Arthrex Hand and Wrist Products

A Multi-Center, Prospective Registry to Evaluate the Continued Safety and Effectiveness of Hand and Wrist Products...

Phoenix, AZ650 participantsArthrex, Inc.

View Study Details

NCT07218926Recruiting

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

The purpose of this study is to find out if a new drug, called IDRX-42 (also known as GSK6042981), is effective in treating adults with a type of cancer called Gastrointestinal Stromal Tumors (GIST) w...

Phoenix, AZPHASE3450 participantsGlaxoSmithKline

View Study Details

NCT05677490Recruiting

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX)...

Phoenix, AZPHASE3382 participantsAlliance for Clinical Trials in Oncology

View Study Details

NCT05377996Recruiting

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

A Study of Emi-Le in Participants with Solid Tumors...

Phoenix, AZPHASE1360 participantsDay One Biopharmaceuticals, Inc.

View Study Details

NCT06349642Recruiting

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy...

Phoenix, AZ324 participantsMayo Clinic

View Study Details

NCT06659445Recruiting

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

The purpose of this study is to collect efficacy and safety information of intravitreal injection for 3 experimental arms, including 2 dose levels of ONL1204 and 2 treatment frequencies in patients wi...

Phoenix, AZPHASE2324 participantsONL Therapeutics

View Study Details

NCT02774746Recruiting

Gastroschisis Outcomes of Delivery (GOOD) Study

The objective of this study is to investigate the hypothesis that delivery at 35 0/7- 35 6/7 weeks in stable patients with gastroschisis is superior to observation and expectant management with a goal...

Phoenix, AZNA300 participantsMedical College of Wisconsin

View Study Details

NCT07260916Recruiting

Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation

MINUTE is a prospective, multi-center, randomized, controlled, blinded assessor, adaptive enrichment design, clinical trial. Eligible patients with spontaneous BGH ≥20 mL will be randomized 1:1 to eit...

Phoenix, AZNA300 participantsIcahn School of Medicine at Mount Sinai

View Study Details

NCT06724237Recruiting

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

This phase III trial compares the effect of high dose chemotherapy and the patients' own (autologous) stem cells to observation only in patients with peripheral T-cell lymphoma who achieved a complete...

Phoenix, AZPHASE3294 participantsEastern Cooperative Oncology Group

View Study Details

NCT06990269Recruiting

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assess...

Phoenix, AZPHASE2240 participantsADARx Pharmaceuticals, Inc.

View Study Details

NCT07215390Recruiting

A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio

A Phase 2, Randomized, Placebo-controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL-3007 in Combination with Syfovre/Pegcetacopla...

Phoenix, AZPHASE2240 participantsApellis Pharmaceuticals, Inc.

View Study Details

NCT07419334Recruiting

Study of ALK-001 on the Progression of Stargardt Disease

This study evaluates the efficacy and safety of investigational study drug ALK-001 in participants 8 to 45 years of age, inclusive, with symptoms and signs of autosomal recessive Stargardt disease (ST...

Phoenix, AZPHASE3230 participantsAlkeus Pharmaceuticals, Inc.

View Study Details

NCT06655246Recruiting

A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

In this clinical trial, the safety, tolerability, and preliminary antitumor activity of ziftomenib in combination with imatinib will be evaluated in adults with gastrointestinal stromal tumors (GIST) ...

Phoenix, AZPHASE1157 participantsKura Oncology, Inc.

View Study Details

NCT07029945Recruiting

A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration

This study aims to evaluate the safety and efficacy of BRX011, an oral medication, taken once daily by participants with geographic atrophy secondary to age-related macular degeneration. The study is ...

Phoenix, AZPHASE1152 participantsBiojiva LLC

View Study Details

NCT07425574Recruiting

A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults

Macular dystrophies are a group of inherited eye conditions that affect the macula. The macula is in the center of the retina, the light sensitive part at the back of the eye. In people with macular d...

Phoenix, AZ90 participantsAstellas Pharma Global Development, Inc.

View Study Details

NCT06624670Recruiting

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

The purpose of this study is to find out whether a medicine called spesolimab helps people with pyoderma gangrenosum (PG). The main aim is to see whether spesolimab leads to closure of PG ulcers. This...

Phoenix, AZPHASE390 participantsBoehringer Ingelheim

View Study Details

NCT07161544Recruiting

A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)

The purpose of the 039-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-039 in participants with Stargardt disease secondary to a biallelic mutation of the...

Phoenix, AZPHASE175 participantsAAVantgarde Bio Srl

View Study Details

NCT07641179Recruiting

A Study to Evaluate MAR002 for Acromegaly

Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in participants with acromegaly...

Phoenix, AZPHASE272 participantsMarea Therapeutics

View Study Details

NCT07419841Recruiting

A Phase 1 Study of the Safety and Tolerability of CTX-10726

This is a Phase 1, open-label, first-in-human study of CTX-10726 monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 Cohorts: Cohort 1 Dose Escal...

Phoenix, AZPHASE170 participantsCompass Therapeutics

View Study Details

NCT07734064Recruiting

A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions

Phoenix, AZPHASE130 participantsAstellas Institute for Regenerative Medicine

View Study Details

NCT06803589Recruiting

Growth Hormone for the Treatment of Gastroparesis

The purpose of this study is to determine whether treatment with Growth Hormone results in symptomatic improvement in patients with gastroparesis....

Phoenix, AZEARLY_PHASE110 participantsMayo Clinic

View Study Details

About Geographic Atrophy Clinical Trials in Phoenix

Geographic atrophy is the advanced form of dry age-related macular degeneration, involving progressive loss of retinal cells. It leads to enlarging blind spots in central vision. Recently approved complement inhibitor therapies can slow progression.

There are currently 30 geographic atrophy clinical trials recruiting participants in Phoenix, AZ. These studies are seeking a combined 26,005 participants. Research is being sponsored by Genzyme, a Sanofi Company, AstraZeneca, Gilead Sciences and 25 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Geographic Atrophy Clinical Trials in Phoenix — FAQ

Are there geographic atrophy clinical trials in Phoenix?

Yes, there are 30 geographic atrophy clinical trials currently recruiting in Phoenix, AZ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Phoenix?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Phoenix research site will contact you about next steps.

Are clinical trials in Phoenix free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Phoenix studies also compensate for your time and travel.

What geographic atrophy treatments are being tested?

The 30 active trials in Phoenix are testing new therapies including novel drugs, biologics, and treatment approaches for geographic atrophy.

Data updated October 15, 2026 from ClinicalTrials.gov